US EditionIvonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
Ivonescimab is the only drug from a Chinese independent R&D company on FirstWord Pharma’s list of 20 key drugs shaping the pharmaceutical industry in 2026.
- FirstWord Pharma added ivonescimab, a PD-1/VEGF bispecific antibody, to its 2026 'Spotlight On' list, announced by Akeso, Inc. on Jan. 28, 2026 in HONG KONG.
- Akeso's internal R&D strength, built since 2012, and its proprietary Tetrabody bispecific platform contributed to ivonescimab's inclusion in FirstWord Pharma's 20-drug list on Jan. 28, 2026.
- Grouped alongside Eli Lilly, AstraZeneca/Daiichi Sankyo, Novartis and Moderna/Merck drugs, ivonescimab represents a multispecific modality within Akeso's pipeline.
- Akeso cautioned that there is no assurance ivonescimab will obtain regulatory approval or achieve commercial success and noted the announcement contains forward‑looking statements not meant as investment advice.
- With a pipeline of over 50 assets, Akeso is advancing a global 'IO 2.0+' strategy supported by 26 clinical-stage candidates and GMP manufacturing infrastructure.
50 Articles
50 Articles
Ivonescimab Included in FirstWord Pharma's 'The Drugs That Will Shape 2026'
HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled 'Spotlight On: The Drugs That Will Shape 2026', providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific…
Bennington Banner
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key…
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
